MeiraGTx Holdings plc MGTX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026
MeiraGTx Holdings plc (MGTX) is a healthcare company listed in the US with a market value of about $897M. In the twelve months to September 30, 2026 it had revenue of $402M and net income of $78M, a net margin of 19.5%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 10.6, 5-year revenue growth of 39% a year, a 5-year average ROIC of -75%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% below the current price.
About MeiraGTx Holdings
MeiraGTx Holdings is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2018. Revenue went from $13M in 2019 to $81M in 2025, growth of about 35.3% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 78% over three years (dilution for shareholders). It spends 159% of revenue on research and development.
Score: 1.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Positive free cash flow
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $402M | $81M | $33M | $14M | $16M | $38M | $16M | $13M | — | — |
| Net income | $78M | -$114M | -$148M | -$84M | -$130M | -$80M | -$58M | -$55M | -$83M | -$31M |
| Free cash flow | -$3M | -$50M | -$109M | -$126M | -$118M | -$57M | -$85M | $11M | -$70M | -$29M |
| EPS (diluted) | $0.87 | $-1.42 | $-2.12 | $-1.49 | $-2.87 | $-1.80 | $-1.54 | $-1.65 | $-4.47 | $-3.72 |
| Net margin | 19.5% | -140.3% | -444.1% | -599.5% | -814.2% | -211.0% | -372.6% | -411.9% | — | — |
| ROIC | — | -128.1% | -107.6% | -60.3% | -43.8% | -34.6% | -24.0% | -27.2% | -95.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $27.75, 202% above the current price; targets range from $16.00 to $50.00; the consensus rating is “Strong buy”; expected EPS is $0.19 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is MeiraGTx Holdings’s P/E ratio?
About 10.6, based on the last twelve months of diluted earnings per share.
Is MeiraGTx Holdings stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 60% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does MeiraGTx Holdings pay a dividend?
Not currently.
Is MeiraGTx Holdings a good stock to buy?
We do not give buy or sell advice. MeiraGTx Holdings scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.